DREAMM-20
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma
Arms / Cohorts
Experimental:Part 1 - Dose escalation of belantamab monotherapy
Accepting patients
Experimental:Part 2 - Belantamab and belantamab mafodotin
Accepting patients
Experimental:Part 1b - Optional belantamab mafodotin
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.